鞘氨醇1磷酸受体调节通过抑制星形胶质细胞活化减轻慢性CRPS小鼠机械性痛觉超敏
该研究在小鼠胫骨骨折/石膏固定CRPS模型的慢性期(骨折后7周),鞘内给予FTY720(每日2.5或25 ng,共6天)可减轻机械性痛觉超敏,机制涉及调节脊髓星形胶质细胞活化。体外数据显示FTY720抑制S1P诱导的一氧化氮产生增加及NF-κB/p65磷酸化,且对星形胶质细胞无毒性。
要点
- 鞘内FTY720在CRPS慢性期仍具有抗痛觉超敏作用
- 其效应与抑制脊髓星形胶质细胞活化相关
- 体外FTY720抑制S1P诱导的NO产生和NF-κB通路
核心结论
- 鞘内注射FTY720可减轻CRPS小鼠模型慢性期的机械性痛觉超敏。
研究设计与样本
- 采用小鼠胫骨骨折/石膏固定CRPS模型,在骨折后7周慢性期鞘内给予FTY720(每日2.5或25 ng,共6天)或溶媒。
主要发现
- 鞘内FTY720在CRPS慢性期产生抗痛觉超敏作用,该作用通过调节脊髓星形胶质细胞活化实现。
- 体外数据显示FTY720抑制S1P诱导的一氧化氮产生增加,并通过抑制星形胶质细胞中NF-κB/p65磷酸化抑制NF-κB通路,且对星形胶质细胞无毒性。
关键数值与推荐
- FTY720剂量为每日2.5或25 ng,鞘内给药6天。
- 行为学评估在骨折后7周慢性期进行。
临床怎么用
- 提示鞘内S1PR调节可能成为CRPS慢性期镇痛策略,但尚需临床研究验证。
局限性
- 证据来自小鼠模型,结论不能直接外推至临床CRPS患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: FTY720 ((2-amino-2-)2-[4-octylphenyl]ethyl)-1,3-propanediol) is an Food and Drug Administration (FDA)-approved immunomodulatory drug for treating multiple sclerosis. It inhibits lymphocyte egression from lymphoid tissues by downregulating sphingosine-1 phosphate receptor (S1PR). To date, there has been no study on the effects of FTY720 on the chronic stage of the complex regional pain syndrome (CRPS) rodent model, despite its antiallodynic effect in previous studies. Thus, the aim of this study is to investigate the effect of FTY720 in a chronic stage of the CRPS mouse model. METHOD: The authors used a mouse model of CRPS, involving tibia fracture/cast immobilization, to test the efficacy of intrathecal FTY720 (2.5 or 25 ng daily; 6 days) or vehicle during the chronic (7 weeks after fracture) stage of CRPS. RESULTS: Intrathecal recombinant FTY720 administration was antiallodynic in the chronic stage of the CRPS mouse model, and such an effect of FTY720 developed by modulating astrocyte activation in the spinal cord. Additionally, according to the in vitro data, the FTY720 treatment inhibited S1P-induced increase in the nitric oxide production and suppression of the NF-κB pathway, by inhibiting the phosphorylation of NF-κB/p65 in astrocytes without toxic effect on astrocytes. CONCLUSION: Collectively, these results demonstrate that intrathecally administered FTY720 attenuates mechanical allodynia in the chronic stage of the CRPS mouse model.
引用
- Lee BJ, Kim JY, Cho HJ, et al. Sphingosine 1-phosphate receptor modulation attenuate mechanical allodynia in mouse model of chronic complex regional pain syndrome by suppressing pathogenic astrocyte activation. Reg Anesth Pain Med. 2020. PMID: 31969447. doi:10.1136/rapm-2019-100801
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。